AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
SI-BONE, Inc.
Video analysis: SIBN
All videosNo video analysis for this stock yet. Request one from our team.
News: SIBN
SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time/ 11:30 a.m. Eastern Time.
Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?
Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade
The mean of analysts' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?
The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SiBone Q2 Earnings Call Highlights
SiBone (NASDAQ: SIBN) reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its expanded product portfolio. Worldwide revenue reached $56 million for the quarter ended June 30, while U.S. revenue increased 14.7% to $53.2 million. International revenue grew 25.9% to
SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript
SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript
Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.14 per share a year ago.
SiBone Q2 Earnings Call Highlights
SiBone NASDAQ: SIBN reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its expanded product portfolio.
Similar companies
-
Orthofix Medical Inc.
OFIX
·
NASDAQ
Compare
-
Pacific Biosciences of California, Inc.
PACB
·
NASDAQ
Compare
-
ClearPoint Neuro, Inc.
CLPT
·
NASDAQ
Compare
-
Butterfly Network, Inc.
BFLY
·
New York Stock Exchange
Compare
-
Innovage Holding Corp.
INNV
·
NASDAQ
Compare
-
AirSculpt Technologies, Inc.
AIRS
·
NASDAQ
Compare